| |
| MARCH
2010 |
|
|
A
clear road to market.
The pharmaceutical sector faces unique challenges
in supply chain management. Delays or disruptions
do not just affect profi ts, they can be a matter
of life and death. Laurent Boer of UCB tells Ian
Duncan how companies can develop robust delivery
strategies. view
pdf
|
A
spoonful of sugar
R&D costs for life sciences have been on the
increase for many years, but at last the pill may
be sweetened by EHR data, which can cut the time
and cost of clinical trials and pretrials, as Deloitte
Life Sciences Division’s Terri Cooper and Glenn
Carroll explain. view
pdf |
|
The
shipping forcast
Transportation is vital in the pharmaceutical
industry, and with more and more focus on how
we use the world’s resources, identifying
ways to ensure shipping is as effi cient and waste-free
as possible, is going to be essential, as Robert
Arendal of Australia’s Cool Chain Association
explains. view
pdf
|
Who
can you trust
Pharmaceutical companies are doing everything
they can to cut capital expenditure, and this
increasingly involves outsourcing operations.
But contracting out any function – whether
it is clinical trials, research and development
or manufacturing – is fraught with diffi
cult decisions. Eric Langer offers some practical
advice on choosing partners, and gives Elly Earls
an insight into the future of the industry. view
pdf
|
Of
mice and men
Despite a commitment to the “Three Rs”
– reduce, replace, refi ne – the number
of procedures involving animal testing is
increasing year-on-year across the EU. Pfi zer’s
Dr David Reynolds tells Phin Foster why such fi
gures can be misleading, and highlights the advancements
being made that may some day see animal studies
become obsolete. view
pdf
|
|
The
rise of the robots
In the increasingly competitive, global and high-expense
world of drug discovery and development, HTS and
HCS have been a vital part of the pharmaceutical
company’s armoury for some time. As the technology
and science around automation and robotics becomes
ever more advanced, their importance is on the
rise, discovers Nic Paton when he talks to robotics
pioneer Dr Ross King. view
pdf
|
Better
by design
The pharmaceutical industry is starting to move
away from a tradition of quality by testing, towards
quality by design. This may be an uncomfortable
time for drug development, but the reward will
be a comfortable future, as Sven Stegemann discovers.
view
pdf
Awash
with ideas
The use of water in the manufacturing process
is vital to the industry, yet its importance is
rarely acknowledged. Ensuring water quality is
essential to the quality of the fi nal product
and to making sure manufacturing processes are
in line with regulations. Dr John Hutcheson explains
the issues surrounding the use of water within
pharmaceuticals, and offers some practical advice.
view
pdf
|
The
future's bright
As the world emerges from one of the most diffi
cult economic climates for a generation, pharmaceutical
executives tell ICD Research – as part of
its research for its latest sector survey –
of their hopes for the short- to mid-term future
of the sector, and share their company’s
future prospects. view
pdf
|
|
Border
control
The risk of counterfeit products infi ltrating
the supply chain is growing ever greater. Colin
Mackay explains how EFPIA’s new coding initiative,
recently piloted in Sweden, provides a model for
an end-to-end verifi cation solution that will
offer robust protection. view
pdf
|
A
latin swing
Latin America is a potential sleeping giant, where
the pharma market has been growing steadily but
quietly. In this report, GlobalData investigates
the market, its drivers and assesses the investment
opportunities. view
pdf
|
Non-stop
action
Continuous manufacturing is the future for the
pharmaceutical industry, but it brings with it
its own series of challenges, as Novartis-MIT
Center’s Professor Bernhardt Trout explains
to Nic Paton. view
pdf
|
| RAW MATERIALS |
SPECIAL REPORT |
|
|
Upwardly
mobile
The CPA believes the APIs market is set to grow
7.2% a year over the next four years. The CPA’s
Marcello Fumagalli examines the sector’s
performance globally, and focuses on China in
particular. view
pdf
|
2010
Pharma 40
World Pharmaceutical Frontiers presents 2010’s
top 40 most infl uential people in the industry,
as judged by our panel of industry experts. Editor
Andrew Tunnicliffe takes stock of the ups and
downs in what has been a turbulent year for everyone.
view
pdf
|
|
